{"id":378965,"date":"2020-11-11T16:08:19","date_gmt":"2020-11-11T21:08:19","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=378965"},"modified":"2020-11-11T16:08:19","modified_gmt":"2020-11-11T21:08:19","slug":"dicerna-to-participate-in-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dicerna-to-participate-in-upcoming-investor-conferences\/","title":{"rendered":"Dicerna to Participate in Upcoming Investor Conferences"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Dicerna to Participate in Upcoming Investor Conferences<\/b><\/p>\n<p>LEXINGTON, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.dicerna.com&amp;esheet=52325311&amp;newsitemid=20201111005841&amp;lan=en-US&amp;anchor=Dicerna+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=ab2ad5381c063b56d27b8157253c3e82\">Dicerna Pharmaceuticals, Inc.<\/a> (Nasdaq: DRNA) (the \u201cCompany\u201d or \u201cDicerna\u201d), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will be participating in fireside chats at two upcoming investor conferences:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Stifel Virtual Healthcare Conference<\/b> on Wednesday, Nov. 18, 2020 at 3:20 p.m. ET\n<\/li>\n<li><b>Evercore ISI 3<sup>rd<\/sup> Annual HealthCONx Virtual Conference<\/b> on Tuesday, Dec. 1, 2020 at 10:05 a.m. ET\n<\/li>\n<\/ul>\n<p>\nA live audio webcast of each event will be accessible from the Investors and Media section of the Dicerna website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.dicerna.com&amp;esheet=52325311&amp;newsitemid=20201111005841&amp;lan=en-US&amp;anchor=www.investors.dicerna.com&amp;index=2&amp;md5=8736187eee38bf432df5da6cd166969b\">www.investors.dicerna.com<\/a>. An archived replay will be available on the Company\u2019s website following the event.\n<\/p>\n<p><b>About Dicerna Pharmaceuticals, Inc.<\/b><\/p>\n<p>\nDicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Using our proprietary RNAi technology platform called GalXC\u2122, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna\u2019s GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on hepatocytes, Dicerna has continued to innovate and is exploring new applications of its RNAi technology beyond the liver, targeting additional tissues and enabling new therapeutic applications. In addition to our own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world\u2019s leading pharmaceutical companies, including Novo Nordisk A\/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and our collaborative partners, we currently have more than 20 active discovery, preclinical or clinical programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegeneration and pain. At Dicerna, our mission is to interfere \u2013 to silence genes, to fight disease, to restore health. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.dicerna.com&amp;esheet=52325311&amp;newsitemid=20201111005841&amp;lan=en-US&amp;anchor=www.dicerna.com&amp;index=3&amp;md5=01392ab579869c40c46c2da1c4b59e95\">www.dicerna.com<\/a>.\n<\/p>\n<p><b>Cautionary Note on Forward-Looking Statements <\/b><\/p>\n<p>\nThis press release includes forward-looking statements pertaining to the Company\u2019s planned participation at investor conferences, which may include discussion of the Company\u2019s business and operations, including the discovery, development and commercialization of our product candidates and technology platform, and the therapeutic potential thereof, the success of our collaborations with partners and any potential future collaborations. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those relating to our preclinical research and clinical programs and other risks identified under the heading \u201cRisk Factors\u201d included in our most recent Form 10-Q filing and in other future filings with the SEC. The forward-looking statements contained in this press release reflect Dicerna&#8217;s current views with respect to future events, and Dicerna does not undertake and specifically disclaims any obligation to update any forward-looking statements.\n<\/p>\n<p>\nGalXC\u2122 is a trademark of Dicerna Pharmaceuticals, Inc.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201111005841r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201111005841\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201111005841\/en\/<\/a><\/span><\/p>\n<p>\nMedia:<br \/>\n<br \/>Amy Trevvett<br \/>\n<br \/>+1 617-612-6253<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:atrevvett@dicerna.com\">atrevvett@dicerna.com<br \/>\n<\/a><\/p>\n<p>Investors:<br \/>\n<br \/>Lauren Stival<br \/>\n<br \/>+1 617-514-0461<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:lstival@dicerna.com\">lstival@dicerna.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Finance Genetics Banking Clinical Trials Professional Services Biotechnology Pharmaceutical Health Science<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20201111005841\/en\/709908\/3\/Dicerna_Logo_with_Trademark_-_Feb-28-2019.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Dicerna to Participate in Upcoming Investor Conferences LEXINGTON, Mass.&#8211;(BUSINESS WIRE)&#8211;Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the \u201cCompany\u201d or \u201cDicerna\u201d), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will be participating in fireside chats at two upcoming investor conferences: Stifel Virtual Healthcare Conference on Wednesday, Nov. 18, 2020 at 3:20 p.m. ET Evercore ISI 3rd Annual HealthCONx Virtual Conference on Tuesday, Dec. 1, 2020 at 10:05 a.m. ET A live audio webcast of each event will be accessible from the Investors and Media section of the Dicerna website at www.investors.dicerna.com. An archived replay will be available on the Company\u2019s website following the event. About Dicerna Pharmaceuticals, Inc. Dicerna &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dicerna-to-participate-in-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Dicerna to Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-378965","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Dicerna to Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dicerna-to-participate-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dicerna to Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Dicerna to Participate in Upcoming Investor Conferences LEXINGTON, Mass.&#8211;(BUSINESS WIRE)&#8211;Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the \u201cCompany\u201d or \u201cDicerna\u201d), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will be participating in fireside chats at two upcoming investor conferences: Stifel Virtual Healthcare Conference on Wednesday, Nov. 18, 2020 at 3:20 p.m. ET Evercore ISI 3rd Annual HealthCONx Virtual Conference on Tuesday, Dec. 1, 2020 at 10:05 a.m. ET A live audio webcast of each event will be accessible from the Investors and Media section of the Dicerna website at www.investors.dicerna.com. An archived replay will be available on the Company\u2019s website following the event. About Dicerna Pharmaceuticals, Inc. Dicerna &hellip; Continue reading &quot;Dicerna to Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dicerna-to-participate-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-11T21:08:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201111005841r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dicerna-to-participate-in-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dicerna-to-participate-in-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Dicerna to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2020-11-11T21:08:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dicerna-to-participate-in-upcoming-investor-conferences\\\/\"},\"wordCount\":563,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dicerna-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201111005841r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dicerna-to-participate-in-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dicerna-to-participate-in-upcoming-investor-conferences\\\/\",\"name\":\"Dicerna to Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dicerna-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dicerna-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201111005841r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-11-11T21:08:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dicerna-to-participate-in-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dicerna-to-participate-in-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dicerna-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201111005841r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201111005841r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dicerna-to-participate-in-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dicerna to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dicerna to Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dicerna-to-participate-in-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Dicerna to Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"Dicerna to Participate in Upcoming Investor Conferences LEXINGTON, Mass.&#8211;(BUSINESS WIRE)&#8211;Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the \u201cCompany\u201d or \u201cDicerna\u201d), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will be participating in fireside chats at two upcoming investor conferences: Stifel Virtual Healthcare Conference on Wednesday, Nov. 18, 2020 at 3:20 p.m. ET Evercore ISI 3rd Annual HealthCONx Virtual Conference on Tuesday, Dec. 1, 2020 at 10:05 a.m. ET A live audio webcast of each event will be accessible from the Investors and Media section of the Dicerna website at www.investors.dicerna.com. An archived replay will be available on the Company\u2019s website following the event. About Dicerna Pharmaceuticals, Inc. Dicerna &hellip; Continue reading \"Dicerna to Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dicerna-to-participate-in-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-11T21:08:19+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201111005841r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dicerna-to-participate-in-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dicerna-to-participate-in-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Dicerna to Participate in Upcoming Investor Conferences","datePublished":"2020-11-11T21:08:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dicerna-to-participate-in-upcoming-investor-conferences\/"},"wordCount":563,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dicerna-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201111005841r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dicerna-to-participate-in-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dicerna-to-participate-in-upcoming-investor-conferences\/","name":"Dicerna to Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dicerna-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dicerna-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201111005841r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-11-11T21:08:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dicerna-to-participate-in-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dicerna-to-participate-in-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dicerna-to-participate-in-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201111005841r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201111005841r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dicerna-to-participate-in-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Dicerna to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/378965","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=378965"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/378965\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=378965"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=378965"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=378965"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}